Streetbeat News

NTRB

Nutriband Inc.

Industry

Biotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Open

4.75

Mkt cap

53M

Volume

11K

High

5.03

P/E Ratio

-5.77

52-wk high

9.60

Low

4.67

Div yield

N/A

52-wk low

2.09

Nutriband announced an $8.4M private placement for 2.10M shares at $4 each, targeting FDA approval for AVERSA Fentanyl by Q1 2025. The deal includes warrants with a $6.43 exercise price. Funds will support AVERSA's clinical development, aiming for peak annual sales of $80M-$200M.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 11:25 am

Kodiak Sciences Inc. shares fell by around 20% after reporting a wider-than-expected Q4 loss. Other stocks showed significant movement, with Avalo Therapeutics leading gainers with a 430% jump after acquiring a Phase 2-ready anti-IL-1β mAb and announcing a private placement financing. Losers included Primech Holdings, falling 46.7% after issuing financial updates. The market saw a mix of positive and negative movements across various sectors.

Portfolio Pulse from Avi Kapoor

March 28, 2024 | 6:08 pm

Health care stocks showed significant movement in Wednesday's intraday session, with notable gainers including Stoke Therapeutics (STOK) up 46.1% following their Q4 earnings release, and Lixte Biotechnology (LIXT) rising 43.68%. On the losing end, Akili (AKLI) dropped 18.8%, and Mesoblast (MESO) declined by 12.85%. Other companies like Nuvation Bio (NUVB), Ontrak (OTRK), PAVmed (PAVM), and Nutriband (NTRB) also saw substantial gains, while Salarius Pharmaceuticals (SLRX), XTL Biopharmaceuticals (XTLB), Fresh2 Group (FRES), and PDS Biotechnology (PDSB) experienced declines.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 4:31 pm

Nutriband shares surged following the company's announcement of a clinical and regulatory path overview for its AVERSA Fentanyl patch.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 1:25 pm

In Wednesday's pre-market session, several healthcare stocks showed significant movement. Lixte Biotechnology, Nutriband, NovoCure, Strata Skin Sciences, Nuvation Bio, and MediciNova were among the gainers, with Lixte Biotechnology leading with a 67.2% increase. On the downside, Akili, OpGen, Mesoblast, Altimmune, Concord Medical Services, and PDS Biotechnology experienced declines, with Akili seeing the largest drop of 20.6%. Notably, Strata Skin Sciences, Altimmune, and PDS Biotechnology released their Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:06 pm

Nutriband announced the clinical development and regulatory pathway for Aversa Fentanyl, an abuse-deterrent fentanyl transdermal patch. The NDA will rely on a single Phase 1 human abuse potential clinical study, bypassing the need for Phase 2 or 3 trials. Aversa Fentanyl combines Nutriband's Aversa technology with an FDA-approved fentanyl patch, developed through a 505(b)(2) NDA pathway.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 9:57 am

In Friday's after-market session, several healthcare stocks showed significant movement. Salarius Pharmaceuticals, Masimo, and Vicarious Surgical were among the top gainers, with Salarius Pharmaceuticals leading with a 33.9% increase. On the downside, NextCure, Rockwell Medical, and Mesoblast experienced declines, with NextCure dropping 9.5% following its Q4 earnings report. These movements reflect the dynamic nature of the healthcare stock market.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 9:33 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. BIOL, OTLK, ETON, MGRM, OTRK, and NTRB were among the gainers, with BIOL leading by surging 61.5% after its Q4 earnings release. On the downside, SINT, CUTR, TBIO, GRFS, YTEN, and NKTX experienced declines, with SINT dropping 34%. CUTR and NKTX also released their Q4 earnings, impacting their stock prices.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 1:06 pm

Nutriband Inc. has signed a commercial development and clinical supply agreement with Kindeva Drug Delivery for Aversa Fentanyl, an abuse-deterrent fentanyl patch. This agreement will enable Kindeva to develop the manufacturing process and produce clinical supplies for FDA-required studies. Aversa Fentanyl, which combines Nutriband's proprietary technology with Kindeva's FDA-approved patch system, has a potential market of $80M - $200M in annual US sales. The technology aims to improve safety while ensuring access for patients in need.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 2:21 pm

Nutriband Inc. has expanded its product line with the launch of AI Tape Heating and Cooling, which are additions to its AI Kinesiology Tape portfolio. These new products aim to provide users with the benefits of both heating and cooling therapy in conjunction with kinesiology taping techniques.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.